Davis Polk advised the joint book-running managers and representatives of the several underwriters in connection with a $115 million SEC-registered common stock offering by Revance Therapeutics, Inc. The common stock is listed on the NASDAQ Global Market under the symbol “RVNC.”
Based in Newark, California, Revance Therapeutics is a specialty biopharmaceutical company developing botulinum toxin products for use in aesthetic and therapeutic indications.
The Davis Polk corporate team included partner Bruce K. Dallas and associates Josephine Chen, Beth LeBow and Blake Anderson. The tax team included partner Rachel D. Kleinberg. The intellectual property and technology team included associate Jason J. Bang. All members of the Davis Polk team are based in the Northern California office.